Vera Therapeutics (VERA) is drawing bullish attention from Wall Street, with multiple analysts significantly raising price targets following a key competitor's FDA approval and revised revenue forecasts for its lead drug candidate.
British Land Company PLC (LON:BLND) finds itself firmly in the hands of institutional investors, who control 88% of its shares. While this signals strong professional backing, it also raises questions about stock volatility and boardroom influence in the UK's property sector.
Keefe Bruyette trimmed its price target on Pagaya Technologies (PGY) to $35, while maintaining an Outperform rating. The adjustment comes despite the AI-driven lending platform reporting robust Q3 growth and a record partner pipeline.
UBS has launched coverage of Arcellx with a Buy rating and a $100 price target, signaling growing Wall Street confidence in a biotech sector recovery and spotlighting the company's promising CAR-T therapy for multiple myeloma.
Despite a lowered price target following an analyst transition, TD Cowen maintains a bullish stance on Alphatec Holdings, citing undervalued growth drivers including a new regenerative bone graft partnership and a robust long-term revenue outlook.
Clinical-stage biopharma Mineralys Therapeutics has filed its New Drug Application for lorundrostat, a potential treatment for resistant hypertension, following positive results from multiple trials. The move positions the company for a potential 2026 market entry and has drawn upgraded price targets from analysts.
Keefe Bruyette significantly raises its price target for Cipher Mining (CIFR), citing the company's strategic expansion into AI and high-performance computing data centers as a key growth driver.
Wall Street firms Keefe Bruyette and BTIG have raised price targets on Core Scientific, citing the company's strategic shift from Bitcoin mining to high-performance computing infrastructure for AI as a key driver for future growth.
Barclays raises Astera Labs' price target to $165, naming it a top pick for AI integration plays in its 2026 semiconductor outlook, while contrasting analyst views highlight the evolving debate on AI's infrastructure demands.
PennyMac Mortgage Investment Trust (PMT) reported a robust fourth quarter, highlighted by a 13% return on equity and strategic advancements in its securitization business. Executives outlined a confident outlook for 2026, emphasizing disciplined risk management and growth in targeted lending segments.
The medical technology giant reports double-digit organic sales growth for the fourth consecutive year, driven by its Mako robotic system and strategic leadership shifts, while navigating tariffs and a shifting competitive landscape.
OSI Systems posts record Q2 revenue and lifts full-year EPS guidance, navigating softness in security bookings and healthcare challenges with optimism for a stronger second half.
Facing a tough freight environment, Schneider National's leadership outlines a strategy centered on cost discipline, tech investment, and strategic positioning in intermodal and dedicated services to steer toward future profitability.
Olin Corporation is closing its Guarujá epoxy facility as part of a broader cost-cutting initiative, responding to soft chlorine demand and operational headwinds. The company pins a turnaround for its Epoxy segment on 2026, while its Winchester ammunition unit raises prices to counter inflation.
SAP discontinues its legacy IS-H healthcare software in the DACH region, impacting dozens of hospitals, while appointing David Robinson to lead its crucial North American operations. The moves signal a strategic pivot as the enterprise software giant navigates a complex market landscape.
KKR & Co.'s shares have retreated over 10% this year, prompting investors to question if the alternative asset manager's long-term growth story justifies its premium valuation. We analyze key metrics and expert narratives to gauge the stock's true appeal.
In a volatile market, certain low-priced Asian stocks are drawing attention not just for their valuation, but for underlying financial strength. We examine three such companies—from healthcare in New Zealand to property services in Greater China—that defy the typical 'penny stock' stereotype with solid fundamentals.
First Internet Bancorp (INBK) reported a robust 21% surge in quarterly revenue, successfully managing an uptick in criticized loans while laying the groundwork for growth in its fintech and SBA lending segments for the coming year.
Despite a 4.3% year-over-year revenue decline in Q3 FY2026, DXC Technology outlines a strategic pivot, leveraging its legacy systems and AI to build scalable IP and shift toward value-based pricing models.
HSBC has upgraded Grab Holdings from Hold to Buy with a $6.20 price target, citing attractive valuation and intact growth drivers. The stock, already on some 'best buy' lists, has surged nearly 5% this week, with Wall Street analysts forecasting significant upside ahead of its Q4 earnings report.
